Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Castle Biosciences Inc
(NQ:
CSTL
)
22.92
+0.24 (+1.06%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Castle Biosciences Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Bragar Eagel & Squire, P.C. Is Investigating Castle, Coinbase, Arrival, and BeiGene and Encourages Investors to Contact the Firm
July 16, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Advance Auto Parts, EPAM, and Castle and Encourages Investors to Contact the Firm
July 10, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Castle Biosciences Inc. (NASDAQ: CSTL) Leading the Way in Friday Trading Based on Percentage Gain
July 07, 2023
Via
Investor Brand Network
Castle Biosciences to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at the American Head & Neck Society’s (AHNS) 11th International Conference on Head and Neck Cancer
July 07, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Advance Auto Parts, EPAM, and Castle Biosciences and Encourages Investors to Contact the Firm
July 05, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating EPAM, Castle, BeiGene and Fox and Encourages Investors to Contact the Firm
June 30, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Study Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology
June 30, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Comerica, Advance Auto Parts, EPAM, and Castle and Encourages Investors to Contact the Firm
June 25, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 20, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Texas Capital, EPAM, and Castle and Encourages Investors to Contact the Firm
June 19, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Kirby McInerney LLP Continues Investigation of Shareholder Claims Against Castle BioSciences, Inc. (CSTL)
June 16, 2023
From
Kirby McInerney LLP
Via
Business Wire
CASTLE ALERT: Bragar Eagel & Squire, P.C. is Investigating Castle Biosciences, Inc. on Behalf of Castle Stockholders and Encourages Investors to Contact the Firm
June 15, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Castle Biosciences Presents New Data Demonstrating the Ability of DecisionDx®-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging
June 12, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Castle Biosciences, Inc. (CSTL)
June 09, 2023
From
Kirby McInerney LLP
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Castle Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
June 06, 2023
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Castle Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
June 05, 2023
From
The Schall Law Firm
Via
Business Wire
Framework Incorporating DecisionDx®-SCC Test Results into Clinical Decision-Making for Patients with High-Risk Cutaneous Squamous Cell Carcinoma Published in Clinical, Cosmetic and Investigational Dermatology
June 05, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting
June 03, 2023
From
Castle Biosciences Inc.
Via
Business Wire
IDgenetix® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder
May 31, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Celebrates Skin Cancer Awareness Month
May 30, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as “Posters of Distinction” by the American Gastroenterological Association (AGA) Institute Council
May 26, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Opens New State-of-the-Art Laboratory in Pittsburgh
May 22, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation
May 15, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Reports First Quarter 2023 Results
May 03, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance Imaging Studies
May 03, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Collaborates with IMPACT Melanoma to Provide Free Sunscreen to Cyclists Participating in the Bike MS: Texas MS 150 2023 Cycling Event
April 28, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients
April 25, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett’s Esophagus Patients with Low-Grade Dysplasia
April 20, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3
April 19, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.